Aurora Awards...

On 28 November, Kerecis announced the Aurora Awards Case Study Competition. Close to twenty case series describing treatment with the Kerecis Omega3 Wound were submitted. They were subsequently...

Get a hands-on...

PRESENT Treasure Hunt is a new comprehensive 2-day education and networking experience aimed at podiatrists based on the west coast. It takes place on January 26-27, 2019, at Hotel Indigo in downtown...

Kerecis featured in...

Fish skin grafts are doctors’ new way to heal wounds on burn victims and diabetics, according to a recent Miami Herald article. In the article, Dr. Lee C. Rogers explains how Kerecis Omega3 rich...

Kerecis Omega3...

‘Fish Skin to Heal Wounds’ by Dr. Christopher L. Winters, DPM, CWS-P, is one of the highlights of the current issue of Podiatry Management. Dr. Winters has 22 years of clinical...

Honoring all who...

Since 2014, Kerecis® has worked with the U.S. Department of Defense and U.S. Department of Veterans Affairs to advance the state of combat wound care and improve treatment for America’s...

Kerecis presenting...

Kerecis will be presenting a workshop on “Debridement and Bolster Protocols for the Use of Kerecis Omega3 Fish Skin in Chronic or Acute Wounds” at the 15th annual Desert Foot Conference. The...

Treating combat...

Kerecis has a long-standing partnership with the U.S. Department of Defense with the aim of developing better remedies for injured American servicemen and women. Kerecis Director of Program...

Icelandic...

Earlier this week Kerecis hosted a delegation of four Icelandic Members of Parliament at the company’s North American offices in the Washington D.C. area. The delegation visited Kerecis before...

Kerecis at...

Kerecis CEO, G. Fertram Sigurjonsson, was one of a handful of experts to present innovations in biotechnology at Maker Faire Rome on October 13. He joined thought leaders and entrepreneurs from...

Meet us at SAWC...

The Symposium on Advanced Wound Care (SAWC) Fall takes place in Las Vegas on November 2 to 4. NEW: DOUBLE-BLIND CLINICAL TRIAL FINDS TREATMENT WITH EPIFIX WAS 76% MORE EXPENSIVE THAN KERECIS OMEGA3...